# Kimia Bio (NSE: KIMIABL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/KIMIABL · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹152 Cr, it ranks 2434th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 96.5% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹27 Cr (−28.9% year on year) and net profit ₹0 Cr (−81.4%), on a standalone basis. Promoters held 74.94% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹152 Cr |
| ROE | 96.5% (FY25) |
| ROCE | 61.9% (FY25) |
| Debt to equity | 3.27 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹27 Cr | −28.9% | ₹0 Cr | −81.4% | ₹0.15 |
| Q3 FY26 | ₹30 Cr | 0.0% | ₹5 Cr | +19.0% | ₹1.15 |
| Q2 FY26 | ₹34 Cr | +20.7% | ₹1 Cr | −36.6% | ₹0.21 |
| Q1 FY26 | ₹24 Cr | +5.3% | ₹1 Cr | −58.3% | ₹0.13 |
| Q4 FY25 | ₹38 Cr | +26.2% | ₹2 Cr | +10.6% | ₹0.42 |
| Q3 FY25 | ₹30 Cr | +15.1% | ₹5 Cr | — | ₹0.97 |
| Q2 FY25 | ₹28 Cr | +16.4% | ₹2 Cr | — | ₹0.34 |
| Q1 FY25 | ₹22 Cr | −7.6% | ₹1 Cr | — | ₹0.30 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹119 Cr | ₹10 Cr |
| FY24 | ₹105 Cr | −₹5 Cr |
| FY23 | ₹129 Cr | −₹9 Cr |
| FY22 | ₹125 Cr | −₹4 Cr |
| FY21 | ₹133 Cr | ₹5 Cr |
| FY20 | ₹106 Cr | ₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 74.94%
- Domestic institutions: 0.38%
- Non-institutions: 24.68%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Bal Pharma](https://app.pivotnow.in/stock/BALPHARMA) | ₹109.58 | ₹174 Cr | 27.7 | — |
| [Vaidya Sane Ayu](https://app.pivotnow.in/stock/MADHAVBAUG) | ₹161.10 | ₹169 Cr | — | — |
| [Natural Capsules](https://app.pivotnow.in/stock/NATCAPSUQ) | ₹162.00 | ₹169 Cr | — | — |
| [Panchsheel Org](https://app.pivotnow.in/stock/PANCHSHEEL) | — | ₹159 Cr | — | — |
| [Auro Labs](https://app.pivotnow.in/stock/AUROLAB) | — | ₹156 Cr | — | — |
| [Smruthi Organic](https://app.pivotnow.in/stock/SMRUTHIORG) | — | ₹135 Cr | — | — |

## Questions and answers

### What is the market cap of Kimia Bio?

Kimia Bio's market capitalisation is ₹152 Cr (₹152 Cr) at the 19 Oct 2026 close, ranking 2434th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Kimia Bio?

Return on equity was 96.5% in FY25 and return on capital employed was 61.9% in FY25 (standalone figures).

### Is Kimia Bio a debt-free company?

No. Kimia Bio's debt-to-equity ratio was 3.27 in FY25, with total debt of ₹10 Cr.

### What were Kimia Bio's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Kimia Bio reported revenue of ₹27 Cr, −28.9% year on year, and net profit of ₹0 Cr, −81.4% year on year.

### What is the shareholding pattern of Kimia Bio?

As of 30 Jun 2026: promoters 74.94%, domestic institutions 0.38%, non-institutions 24.68%.

### Who are Kimia Bio's competitors?

The listed Pharma & Healthcare companies closest to Kimia Bio by market cap are Bal Pharma, Vaidya Sane Ayu, Natural Capsules, Panchsheel Org, Auro Labs and Smruthi Organic.

### Is Kimia Bio a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Kimia Bio's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KIMIABL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.